Company intelligence
RA Capital Management
About RA Capital Management
Founded in 2004, RA Capital Management is an active, multi-stage investment manager dedicated to evidence-based, science-led investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital's knowledge engine is guided by our TechAtlas team which brings insight, deep analysis and scientific rigor to our diligence process. Raven, RA Capital’s healthcare incubator, offers biomedical entrepreneurs and innovators a collaborative and comprehensive platform to explore novel solutions to address unmet patient needs and to unlock value from existing but underleveraged assets. RA Capital has more than 250 employees and over $14 billion in assets under management, and we are working to build a happier, healthier, more productive future for all.
Verified activity
Signals from RA Capital Management
10 published signals
Capital & Finance
RA Capital Management supported Superluminal Medicines Inc. with $60M Series B funding to transition from discovery platform to clinical-stage biotech, with a Phase 1 trial expected to begin by the end of 2026.
Reported by RA Capital Management
Capital & Finance
RA Capital Management backed Superluminal Medicines Inc. with $60M Series B funding to advance a selective, biased MC4R agonist designed to activate signaling pathways responsible for rare genetic forms of obesity.
Reported by RA Capital Management
Presence & Recognition
RA Capital Management Managing Director Tess Cameron will be joined by Partner Ken Song, Founding Partner Simone Song, and President John F. Crowley at the Cantor Fitzgerald Global Healthcare Conference panel on September 10th.
Reported by RA Capital Management
Presence & Recognition
RA Capital Management noted that the FDA is getting funding to inspect more sites around the world.
Reported by Peter Kolchinsky
Partnerships
RA Capital Management partnered with AM Batteries to remove NMP from the traditional battery manufacturing process.
Reported by RA Capital Management
Capital & Finance
RA Capital Management is seeing public and private capital treating domestic battery manufacturing infrastructure as a strategic asset rather than an afterthought.
Reported by Kathryn Meng
Research & Knowledge
RA Capital Management published that Slate is dosing its first person with its novel migraine drug candidate, which uniquely hits two potential triggers of migraine.
Reported by Peter Kolchinsky
Products & Services
RA Capital Management funded FAB1, a new Massachusetts microfactory producing up to 500 multifamily units a year using less than $5M of equipment.
Reported by Kathryn Meng
Capital & Finance
RA Capital Management announced $40M in new financing led by Energy Impact Partners, with continued support from RA Capital Management's Planetary Health Fund and other existing investors.
Reported by Kathryn Meng
Customers & Market
RA Capital Management backed Reframe as they build toward one million homes by 2040.
Reported by Kathryn Meng